Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dexlansoprazole Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00255164
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

NCT00230516
View directory record Official record
Conditions
Healthy
Interventions
Nexium, Prevacid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 21, 2026, 5:20 AM EDT
Completed No phase listed Observational

Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only

NCT01536457
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Children's Center for Digestive Health Care
Other
Eligibility
4 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395
View directory record Official record
Conditions
Heartburn, Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

NCT00546117
View directory record Official record
Conditions
Otitis Media With Effusion
Interventions
lansoprazole, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Lansoprazole to Treat Children With Asthma

NCT00442013
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole, Matching placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2011 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Replicate Food Study

NCT01046084
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Lansoprazole in Chronic Post Nasal Drip

NCT00335283
View directory record Official record
Conditions
Larynx Disease
Interventions
Lansoprazole Tablet, PH and impedence testing, manometry, lansoprazole, placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 21, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

NCT02615184
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

NCT00444145
View directory record Official record
Conditions
Larynx Disease, Gastroesophageal Reflux
Interventions
Prevacid, Esophageal and Laryngeal Biopsies
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

NCT00701259
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Lansoprazole, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 21, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Results available

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

NCT00637416
View directory record Official record
Conditions
Dysphonia
Interventions
Lansoprazole, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

NCT00295685
View directory record Official record
Conditions
GERD
Interventions
Antacids
Drug
Lead sponsor
Digestive & Liver Disease Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 4 Interventional

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

NCT00410592
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Anaheim, California • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 21, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

NCT03015610
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux
Interventions
commercially available lansoprazole, matched placebo
Drug
Lead sponsor
Jason Lang, M.D., M.P.H.
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 21, 2026, 5:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection

NCT02788591
View directory record Official record
Conditions
Non-erosive Reflux Disease, Gastroesophageal Reflux
Interventions
Proton Pump Inhibitor (PPI) Therapy, Sucralfate
Drug
Lead sponsor
LCMC Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 21, 2026, 5:20 AM EDT